📊 CCEL Key Takeaways
Is Cryo Cell International Inc. (CCEL) a Good Investment?
Cryo Cell International demonstrates severe financial distress with negative stockholders' equity of -18.6M, indicating the company is technically insolvent. Despite modest positive operating cash flow, the company faces critical liquidity constraints with a current ratio of 0.59x and only 319K in cash against 80.3M in total liabilities. Deteriorating profitability with -7.7% net margins and declining revenue suggests structural business challenges that pose existential risk to the enterprise.
Cryo-Cell International shows weak core fundamentals: revenue is slightly declining, operating margin is only 1.5%, and the company remains unprofitable at the net income level. Financial health is the main concern, with negative equity, very weak liquidity, minimal cash on hand, and poor interest coverage, which outweigh the benefit of currently positive operating and free cash flow.
Why Buy Cryo Cell International Inc. Stock? CCEL Key Strengths
- Positive operating cash flow of 5.5M provides near-term runway despite negative net income
- Free cash flow margin of 16.6% indicates cash-generative operations when excluding capital investments
- Operating income positive at 482.4K shows core business generates some profitability before financing costs
- Positive operating cash flow and free cash flow generation despite reported net losses
- Business remains slightly profitable at the operating income level
- Capital expenditure requirements appear relatively low, supporting near-term free cash flow
CCEL Stock Risks: Cryo Cell International Inc. Investment Risks
- Negative stockholders' equity of -18.6M indicates technical insolvency and severe balance sheet deterioration
- Critical liquidity crisis with current ratio of 0.59x and minimal cash reserves of 319K against substantial liabilities
- Deteriorating earnings with negative net margin of -7.7% and declining revenue; interest coverage ratio of 0.2x indicates inability to service debt from operations
- Liabilities exceed assets by 18.6M, creating existential solvency risk and potential covenant violations
- Negative stockholders' equity indicates a highly stressed balance sheet
- Current ratio of 0.59x and cash of only $319K signal meaningful liquidity risk
- Interest coverage of 0.2x suggests limited ability to service debt from operations
Key Metrics to Watch
- Stockholders' equity trend - critical indicator of solvency recovery or further deterioration
- Operating cash flow sustainability - essential lifeline given negative net income and tight liquidity
- Revenue stabilization and gross profitability improvement - currently insufficient to cover operating costs and debt service
- Sustained operating cash flow versus net losses
- Liquidity improvement, especially cash balance and current ratio
Cryo Cell International Inc. (CCEL) Financial Metrics & Key Ratios
💡 AI Analyst Insight
The current ratio below 1.0x warrants monitoring of short-term liquidity.
CCEL Profit Margin, ROE & Profitability Analysis
CCEL vs Services Sector: How Cryo Cell International Inc. Compares
How Cryo Cell International Inc. compares to Services sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Cryo Cell International Inc. Stock Overvalued? CCEL Valuation Analysis 2026
Based on fundamental analysis, Cryo Cell International Inc. has mixed fundamental signals relative to the Services sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Cryo Cell International Inc. Balance Sheet: CCEL Debt, Cash & Liquidity
CCEL Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Cryo Cell International Inc.'s revenue has shown modest growth of 3% over the 5-year period. The most recent EPS of $0.05 reflects profitable operations.
CCEL Revenue Growth, EPS Growth & YoY Performance
CCEL Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $7.7M | $47.1K | $0.01 |
| Q3 2025 | $7.8M | $749.4K | $0.09 |
| Q2 2025 | $7.9M | $355.8K | $0.04 |
| Q1 2025 | $7.9M | $282.9K | $0.03 |
| Q3 2024 | $7.9M | $680.6K | $0.08 |
| Q2 2024 | $7.8M | $221.0K | $0.03 |
| Q1 2024 | $7.8M | $556.2K | $0.07 |
| Q3 2023 | $7.7M | $466.8K | $0.06 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Cryo Cell International Inc. Dividends, Buybacks & Capital Allocation
CCEL SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Cryo Cell International Inc. (CIK: 0000862692)
📋 Recent SEC Filings
❓ Frequently Asked Questions about CCEL
What is the AI rating for CCEL?
Cryo Cell International Inc. (CCEL) has a Combined AI Rating of STRONG SELL from Claude (STRONG SELL) and ChatGPT (STRONG SELL) with 86% combined confidence, based on fundamental analysis of SEC EDGAR filings.
What are CCEL's key strengths?
Claude: Positive operating cash flow of 5.5M provides near-term runway despite negative net income. Free cash flow margin of 16.6% indicates cash-generative operations when excluding capital investments. ChatGPT: Positive operating cash flow and free cash flow generation despite reported net losses. Business remains slightly profitable at the operating income level.
What are the risks of investing in CCEL?
Claude: Negative stockholders' equity of -18.6M indicates technical insolvency and severe balance sheet deterioration. Critical liquidity crisis with current ratio of 0.59x and minimal cash reserves of 319K against substantial liabilities. ChatGPT: Negative stockholders' equity indicates a highly stressed balance sheet. Current ratio of 0.59x and cash of only $319K signal meaningful liquidity risk.
What is CCEL's revenue and growth?
Cryo Cell International Inc. reported revenue of $31.6M.
Does CCEL pay dividends?
Cryo Cell International Inc. pays dividends, with $3.2M distributed to shareholders in the trailing twelve months.
Where can I find CCEL SEC filings?
Official SEC filings for Cryo Cell International Inc. (CIK: 0000862692) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is CCEL's EPS?
Cryo Cell International Inc. has a diluted EPS of $-0.30.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is CCEL a good stock to buy right now?
Based on our AI fundamental analysis in April 2026, Cryo Cell International Inc. has a STRONG SELL rating with 86% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is CCEL stock overvalued or undervalued?
Valuation metrics for CCEL: ROE of N/A (sector avg: 16%), net margin of -7.7% (sector avg: 10%). Compare these metrics with sector averages to assess valuation.
Should I buy CCEL stock in 2026?
Our dual AI analysis gives Cryo Cell International Inc. a combined STRONG SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is CCEL's free cash flow?
Cryo Cell International Inc.'s operating cash flow is $5.5M, with capital expenditures of $230.5K. FCF margin is 16.6%.
How does CCEL compare to other Services stocks?
Vs Services sector averages: Net margin -7.7% (avg: 10%), ROE N/A (avg: 16%), current ratio 0.59 (avg: 1.5).